SCHEMBL17452655

SCHEMBL17452655

Cc1c(OCc2ccccc2)ccc2c(C(=O)C(C)C)cnn12

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 4/20 0.43
▸ L3MBTL1 Q9Y468 3/20 0.43
▸ MAPT P10636 2/20 0.43
▸ CYP2C9 P11712 2/20 0.43
▸ CYP2C19 P33261 2/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ FFAR4 Q5NUL3 1/20 0.39
▸ PTGER1 P34995 8/20 0.39
▸ LRRK2 Q5S007 1/20 0.39
▸ KDM4E B2RXH2 3/20 0.39
▸ CYP1A2 P05177 2/20 0.39
▸ ALKBH1 Q13686 3/20 0.38
▸ FOLH1 Q04609 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ POLB P06746 1/20 0.38
▸ PTGER4 P35408 1/20 0.38
▸ PTGER3 P43115 1/20 0.38
▸ PTGER2 P43116 1/20 0.38
▸ MAPK1 P28482 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17454421 0.87 TDP1 (0.54) TDP1L3MBTL1MAPTCYP2C9CYP2C19
SCHEMBL17437984 0.85 MAPT (0.44) TDP1L3MBTL1MAPTCYP2C9CYP2C19
SCHEMBL17452672 0.84 GRM2 (0.41) TDP1L3MBTL1MAPTCYP2C9CYP2C19
SCHEMBL17452658 0.84 XDH (0.41) TDP1L3MBTL1MAPTCYP2C9CYP2C19
SCHEMBL17452659 0.84 MEN1 (0.39) TDP1L3MBTL1MAPTCYP2C9CYP2C19
SCHEMBL17452656 0.84 ROCK2 (0.40) TDP1LRRK2KDM4EALDH1A1
SCHEMBL17452634 0.77 ALKBH1 (0.43) L3MBTL1ALKBH1
SCHEMBL17437909 0.74 PTGER1 (0.43) TDP1L3MBTL1PTGER1LRRK2CYP1A2
SCHEMBL6816963 0.74 SGMS2 (0.57) TDP1L3MBTL1MAPTPTGER1KDM4E
SCHEMBL17437885 0.73 NOTUM (0.43) TDP1L3MBTL1MAPTCYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180155296-A1 SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK BRISTOL MYERS SQUIBB CO (US) 2018-06-07 — — US disclosed
US-9902702-B2 Spirocycloheptanes as inhibitors of rock BRISTOL-MYERS SQUIBB COMPANY (US) 2018-02-27 — — US disclosed
US-9902702-B2 Spirocycloheptanes as inhibitors of rock BRISTOL-MYERS SQUIBB COMPANY (US) 2018-02-27 — — US disclosed
US-20160016914-A1 SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK BRISTOL-MYERS SQUIBB COMPANY 2016-01-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180155296-A1 SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK ROCK1, MYLK, ROCK2 TDP1 682/4885L3MBTL1 4810/4885MAPT 171/4885
US-20160016914-A1 SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK ROCK1, MYLK, ROCK2 TDP1 682/4885L3MBTL1 4810/4885MAPT 171/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback